Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Citius Pharmaceuticals, Inc. CTXR NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
33/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Citius Pharmaceuticals, Inc. (CTXR) is a Biotechnology company in the Healthcare sector, currently trading at $0.86. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: CTXR trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25).

Net income is $37M (loss), growing at -4.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $68M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 0.62 (tight liquidity). Debt-to-assets is 1.4%. Total assets: $131M.

Analyst outlook: 5 / 6 analysts rate CTXR as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).

CTXR SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 90/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CTXR

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
CTXR: +0%/yr revenue is, -4.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet CTXR: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 0.62 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
CTXR: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
90/100
Analyst outlook: 5 / 6 analysts rate CTXR as buy (83%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.63-2.48
Volume314.07K
Avg Volume (30D)561.51K
Market Cap$9.57M
Beta (1Y)1.38
Share Statistics
EPS (TTM)-3.38
Shares Outstanding$11.07M
IPO Date2014-10-02
Employees23
CEOLeonard L. Mazur
Financial Highlights & Ratios
Gross Profit$-214.25K
EBITDA$-38.2M
Net Income$-37.43M
Operating Income$-38.53M
Total Cash$4.25M
Total Debt$1.81M
Net Debt$-2.44M
Total Assets$130.94M
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering6
Buy 83% Hold 17% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS17322U3068

Price Chart

Track all markets on TradingView
CTXR
Citius Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.63 52WK RANGE 2.48

People Also View

IBRX
IBRX
ImmunityBio, Inc.
$7.78
+2.37%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 ARDX
ARDX
Ardelyx, Inc.
$6.30
-0.47%
 LXRX
LXRX
Lexicon Pharmaceuticals, Inc.
$1.86
+6.29%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 MCRB
MCRB
Seres Therapeutics, Inc.
$8.84
+2.67%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message